Sensus (SRTS) Q2 Revenue Falls 21%

Sensus Healthcare (NASDAQ:SRTS) reported a substantial Q2 2025 financial miss, with GAAP revenue of $7.3 million falling 20.7% year-over-year and well below the $9.3 million estimate, resulting in a GAAP net loss of $0.06 per share compared to a profit last year. This underperformance was primarily attributed to lower SRT system sales, domestic sales disruption from proposed insurance reimbursement limits, and a sharp gross margin contraction to 39.7% due to higher costs. Management is focusing on scaling recurring revenue through Fair Deal Agreements and international expansion, with significant FDA contributions expected in H2 2025, as the company navigates ongoing market and operational challenges.

Analysis

Sensus Healthcare's Q2 2025 results revealed a significant deterioration in financial performance, characterized by substantial misses on both revenue and earnings. GAAP revenue of $7.3 million fell 20.7% year-over-year and landed significantly below the $9.3 million consensus estimate, driven primarily by a reduction in SRT system sales and a mid-quarter disruption from a proposed insurance reimbursement limit that impacted domestic sales. The company swung to a GAAP net loss of $0.06 per share, a stark reversal from the $0.10 profit in the prior-year period. Profitability was severely eroded, with gross margin contracting by 19 percentage points to 39.7% due to lower sales volume and higher service costs. This top-line pressure was compounded by rising operating expenses in R&D, sales, and administration, resulting in a negative adjusted EBITDA of $1.8 million. While the company is strategically pivoting towards a recurring revenue model with its Fair Deal Agreements (FDAs), which grew 27% quarter-over-quarter, this growth was insufficient to offset the decline in capital equipment sales. Management withheld formal guidance, signaling significant near-term uncertainty, although they anticipate a meaningful contribution from FDAs in the second half of 2025. The balance sheet remains debt-free with a stable cash position of $22.2 million, but a 23% increase in inventory since year-end to $12.4 million could indicate slowing demand.

Key Decisions for Investors

• Given the severe earnings miss, collapsing margins, and negative reimbursement outlook, investors should treat the equity with caution until there is clear evidence of a turnaround in the core equipment business.
• The primary focus should be on the pace of the Fair Deal Agreement (FDA) ramp-up, as management has positioned this recurring revenue stream as the key driver for recovery in the second half of 2025.
• Monitor inventory levels closely, as the increase to $12.4 million could signal future margin pressure or write-downs if sales momentum does not improve.
• Investors should watch for any definitive news on the proposed Medicare reimbursement changes for 2026, as a favorable outcome could serve as a significant long-term catalyst, while an unfavorable one would compound existing headwinds.